Leica Biosystems Expands Collaboration to Enhance Precision Medicine through AI Diagnostics

Leica Biosystems Expands Collaboration for AI-Powered Diagnostics

Leica Biosystems, a prominent player in the field of anatomic and digital pathology solutions and part of Danaher Corporation, has announced an exciting expansion of its collaboration with AstraZeneca and Daiichi Sankyo. This strategic move aims to enhance the development of an advanced system focusing on TROP2 NMR (Normalized Membrane Ratio) for non-small cell lung cancer (NSCLC). This latest collaboration further emphasizes the role of artificial intelligence (AI) in medical diagnostics, marking another step towards improving precision medicine.

Expanding Strategic Collaborations

The initiative, which first gained momentum in May 2025, leverages AstraZeneca’s computational pathology algorithm known as Quantitative Continuous Scoring (QCS). This will be paired with the advanced capabilities of Leica Biosystems in digital pathology solutions and immunohistochemistry (IHC) assay development. The goal is to create an end-to-end solution that incorporates innovative tools for assessing novel biomarkers associated with NSCLC. These advancements aim to identify patients who may benefit most from targeted cancer therapies.

Gustavo Perez-Fernandez, the Group Executive for Diagnostics at Danaher and President of Leica Biosystems, stated, "Advancing cancer diagnostics requires more than individual innovations; it demands collaboration across science, technology, and workflow." By merging the expertise of AstraZeneca and Daiichi Sankyo, the collaboration seeks to address the intricate challenges faced in biomarker research.

Transforming the Pathology Landscape

As the field of pathology evolves, there is a noticeable push towards digital workflows supported by technologies such as whole-slide imaging (WSI) and advanced AI algorithms. The ongoing collaboration is positioned to exploit Leica Biosystems' BOND RX research stainer, BOND-III clinical stainer, Aperio GT 450 scanner, and Aperio HALO AP image management system for efficient development and deployment of computational image analysis algorithms. These technologies will allow for quicker advancements in diagnostic processes and broader application globally.

Karan Arora, Senior Vice President of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems, remarked, "This collaboration reflects the industry's shift toward integrated best-in-class open digital ecosystems." With their longstanding prowess in digital pathology, Leica Biosystems aims to support laboratories in adopting new computational workflows effectively.

Promoting the Future of Precision Medicine

Leica Biosystems' commitment to enhancing computational pathology is evident in its innovative approaches aimed at delivering improved diagnostic capabilities. Their focus on establishing a thorough diagnostic development pathway, extending from early assay feasibility to global implementation, aligns with their mission to promote advancements in cancer diagnostics that ultimately lead to better patient outcomes.

In summary, the collaborative effort between Leica Biosystems, AstraZeneca, and Daiichi Sankyo represents a significant leap towards the future of precision medicine. As diagnostics become increasingly precise and efficient through the use of AI and advanced algorithms, the potential for transformative impacts on patient care becomes clearer. As this partnership progresses, it is expected to play a crucial role in enhancing diagnostic accuracy and the overall efficacy of treatment plans for lung cancer patients.

Note: This collaboration initiative is designed for research purposes only and is not intended for use in diagnostic procedures.

About Leica Biosystems

Leica Biosystems is recognized globally for its leadership in providing comprehensive solutions across the pathology process. The company is well-positioned as it owns the entire workflow from biopsy to diagnosis, aiming to break down barriers in cancer diagnostics and contribute toward the improvement of patient lives. Founded on the principles of advancing cancer diagnostics and improving lives, Leica Biosystems remains steadfast in its mission to reshape the future of diagnostic processes through innovation and strategic partnerships.

About Danaher

Danaher Corporation is committed to driving the power of science and technology to foster innovations that improve human health. As it supports its various businesses within the life sciences and diagnostics sector, Danaher emphasizes collaboration with its customers to tackle complex scientific and clinical challenges, ensuring faster access to essential innovations beneficial to patient care.